AGENDA - Main Workshop DAY 1
June 17, 2020, 11am to 4pm ET: Part 1
June 18, 2020, 11am to 5pm ET: Part 2

Mass Spectrometry DAY - Part 1: June 17, 2020 (EDT time listed)

11:00am-11:10am: Dr. Christopher Evans, Sr. Director Bioanalysis, Immunogenicity & Biomarker, GlaxoSmithKline
"Introduction of Mass Spectrometry DAY - Part 1"

Innovations in Small Molecules & Novel solutions

Chair: Dr. Christopher Evans, Sr. Director Bioanalysis, Immunogenicity & Biomarker, GlaxoSmithKline
11:10am-11:30am: Dr. Jens Sydor, Vice President DMPK, GlaxoSmithKline
"Microbiome Contributions to Drug Metabolism and its Impact on Bioanalysis"
11:30am-11:50am: Dr. Jason Boer, Assoc. Director DMPK, Incyte Corporation
"Gut Metabolism: Small molecules case studies, bioanalytical method development and considerations on a new paradigm in metabolite quantification"
11:50am-12:10pm: Dr. Brian Dean, Director DMPK, Genentech
"Challenges in Quantitation of Short Chain Fatty Acids (SCFA) Endogenous Small Molecules Biomarkers: Genentech Experience, DMPK & Bioanalytical Perspective and Evolving Trends"
12:10pm-12:40pm: Dr. Jens Sydor, Vice President DMPK, GlaxoSmithKline
Dr. Jason Boer, Assoc. Director DMPK, Incyte Corporation
Dr. Brian Dean, Director DMPK, Genentech
Dr. Christopher Evans, Sr. Director Bioanalysis, Immunogenicity & Biomarker, GlaxoSmithKline
"Panel Discussion on Microbiome"
12:40pm-01:10pm: Social Networking - Time to "Visit" Exhibitors and Posters
01:10pm-01:30pm: Dr. Timothy Olah, Group Director Bioanalytical Research, Bristol-Myers Squibb
"Status Report on the Success of the PROTAC Strategy as a Small Molecule Therapeutic Modality: On-going bioanalytical challenges"
01:30pm-01:50pm: Dr. Hui Zhang, Assoc. Research Fellow Discovery Science, Pfizer
"Novel developments in Acoustic Mass Spectrometry (Acoustic-MS) for Bioanalytical Applications: Learnings About ADE-OPI-MS Technology and Future Perspectives"
01:50pm-02:10pm: Dr. Kevin Bateman, Scientific Associate VP and Scientific Lead Bioanalysis, Merck
"Novel developments in Acoustic Mass Spectrometry (Acoustic-MS) for Bioanalytical Applications: Quantitative Analysis Using Echo-MS"
02:10pm-02:40pm: Dr. Timothy Olah, Group Director Bioanalytical Research, Bristol-Myers Squibb
Dr. Hui Zhang, Assoc. Research Fellow Discovery Science, Pfizer
Dr. Kevin Bateman, Scientific Associate VP and Scientific Lead Bioanalysis, Merck
Dr. Christopher Evans, Sr. Director Bioanalysis, Immunogenicity & Biomarker, GlaxoSmithKline
"Panel Discussion on PROTAC & Acoustic-MS"
02:40pm-03:10pm: Social Networking - Time to "Visit" Exhibitors and Posters

2020 White Paper on Innovations in Small Molecules Bioanalysis & Novel Solutions

03:10pm-03:30pm: Dr. Scott Summerfield, Sr. Director and UK Head of Bioanalysis and Biomarkers,GlaxoSmithKline
Dr. Christopher Evans, Sr. Director Bioanalysis, Immunogenicity & Biomarker, GlaxoSmithKline
"Consensus & Recommendations on in Small Molecules Bioanalysis & Novel solution in Mass Spectrometry"
03:30pm-04:00pm: Small Molecules Bioanalysis & Novel Solutions White Paper Working Experts Group
"Panel Discussion on Innovations in Small Molecules Bioanalysis & Novel Solutions in Mass Spectrometry"


Mass Spectrometry DAY - Part 2: June 18, 2020 (EDT time listed)

11:00am-11:10am: Dr. Christine Fandozzi, Associate Vice President Global Bioanalytical Group, Merck
"Introduction of Mass Spectrometry DAY - Part 2"

Regulatory Challenges in Mass Spectrometry Bioanalysis

Chair: Dr. Christine Fandozzi, Associate Vice President Global Bioanalytical Group, Merck
11:10am-11:30am: Ms. Daniela Fraier, Head of Small Molecules Regulatory Bioanalysis, Roche
"Innovative Bioanalytical Approaches in Juvenile & Pediatric Studies: Building on WRIB Recommendations and Evolving Trends"
11:30am-11:50am: Ms. Amanda Wilson, Head Translational Biomarkers and Bioanalysis, AstraZeneca
"Bioanalytical Solutions Supporting our Endeavors to Find Patient and Environmentally Friendly Formulations"
11:50am-12:10pm: Dr. Christine Fandozzi, Associate Vice President Global Bioanalytical Group, Merck
"Microsampling & Patient Centric Sampling in Regulated Bioanalysis"
12:10pm-12:30pm: Dr. Chris Beaver, Sr. Director Bioanalysis, Syneos Health
"Complexity in the Regulated Bioanalysis of Cannabis: What it is meaningful to measure from the over hundred cannabinoids in cannabis, major active metabolites, and considerations in a regulated environment from different products and formulations"
12:30pm-01:00pm: Social Networking - Time to "Visit" Exhibitors and Posters
01:00pm-01:30pm: Ms. Daniela Fraier, Head of Small Molecules Regulatory Bioanalysis, Roche
Dr. Christine Fandozzi, Associate Vice President Global Bioanalytical Group, Merck
Ms. Amanda Wilson, Head Translational Biomarkers and Bioanalysis, AstraZeneca
Dr. Chris Beaver, Sr. Director Bioanalysis, Syneos Health
Dr. Christine Fandozzi, Associate Vice President Global Bioanalytical Group, Merck
"Panel Discussion on Regulatory Challenges in Mass Spectrometry Bioanalysis"

2020 White Paper on Regulatory Challenges in Mass Spectrometry Bioanalysis

01:30pm-01:50pm: Dr. Christine Fandozzi, Associate Vice President Global Bioanalytical Group, Merck
"Consensus & Recommendations on Regulatory Challenges in Mass Spectrometry Bioanalysis"
01:50pm-02:20pm: Regulatory Challenges in Bioanalysis White Paper Working Experts Group
"Panel Discussion on Regulatory Challenges in Mass Spectrometry Bioanalysis"

HRMS and Hybrid LCMS Assays

Chair: Dr. Stephen Alley, Executive Director Scientific Integration and Strategy, Seattle Genetics
02:20pm-02:40pm: Dr. Wenying Jian, Group Lead and Sr. Principal Scientist DMPK, Janssen
"Current Developments in Intact Protein Therapeutics Bioanalysis by HRMS: Building on WRIB Recommendations, New Case Studies and Evolving Trends"
02:40pm-03:00pm: Dr. Jiang Wu, Director Clinical Biomarker Innovation and Development, Takeda
"Progresses and Innovation in LC-MS Quantification of Protein Therapeutics to Overcome Interferences in LBA"
03:00pm-03:20pm: Dr. Hongbin Yu, Director Bioanalytical Mass Spectrometry, Boehringer Ingelheim
"Novel Applications of Hybrid LBA/LCMS for Target Engagement Biomarkers: Challenges in Using Hybrid LBA/LCMS as Platform for TE, from Assay Format Design to Fit-for-Purpose Validation Experiments"
03:20pm-03:50pm: Social Networking Break - Time to "Visit" Exhibitors and Posters
03:50pm-04:20pm: Dr. Wenying Jian, Group Lead and Sr. Principal Scientist DMPK, Janssen
Dr. Jiang Wu, Director Clinical Biomarker Innovation and Development, Takeda
Dr. Hongbin Yu, Director Bioanalytical Mass Spectrometry, Boehringer Ingelheim
Dr. Stephen Alley, Executive Director Scientific Integration and Strategy, Seattle Genetics
"Panel Discussion on HRMS and Hybrid LCMS Assays"

2020 White Paper on HRMS and Hybrid LCMS Assays

04:20pm-04:40pm: Dr. Stephen Alley, Executive Director Scientific Integration and Strategy, Seattle Genetics
Dr. Hendrik Neubert, Sr. Director Translational Biomeasures and Protein Biomarkers Group, Pfizer
"Consuensus & Recommendations on HRMS and Hybrid LCMS Assays"
04:40pm-05:10pm: HRMS and Hybrid LCMS Assays White Paper Working Experts Group
"Panel Discussion on HRMS and Hybrid LCMS Assays"




Final Agenda Agenda at a Glance